Literature DB >> 27872051

Management of mild hypertension in adults.

Anthony J Viera1, Emily M Hawes1.   

Abstract

Elevated blood pressure is a common risk factor for cardiovascular disease and affects one in three adults. Blood pressure lowering drugs substantially reduce the risk of stroke, coronary heart disease, heart failure, and premature death, but most clinical trials showing benefits have primarily included patients with moderate to severe hypertension, known cardiovascular disease, or elevated risk of cardiovascular disease. The benefits of treating mild hypertension in patients without cardiovascular disease are less clear, but recent meta-analyses offer some insights. Pooled data from trials that include a large percentage of participants with mild hypertension show significant reductions in stroke, death from cardiovascular disease, and total mortality. Meta-analyses comparing lower blood pressure targets also suggest a benefit of treating patients with mild hypertension, although net benefits are greater for patients at higher absolute levels of cardiovascular disease risk. Before starting drug treatment, most patients should have out-of-office monitoring to confirm hypertension. Lifestyle modifications for reducing blood pressure are appropriate for all patients and may be recommended while delaying drug treatment for those at lower absolute levels of cardiovascular disease risk. Patient level control of blood pressure is supported by home monitoring and by once daily, low cost drug. Control of blood pressure for a population of patients is enhanced by system level interventions such as registries, implementation of evidence based protocols, drug titration visits, and performance metrics. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27872051     DOI: 10.1136/bmj.i5719

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  7 in total

1.  Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.

Authors:  Martin Bødtker Mortensen; Børge Grønne Nordestgaard
Journal:  JAMA Cardiol       Date:  2019-11-01       Impact factor: 14.676

2.  Home Blood Pressure Monitoring in Cases of Clinical Uncertainty to Differentiate Appropriate Inaction From Therapeutic Inertia.

Authors:  Sonal J Patil; Nuha K Wareg; Kelvin L Hodges; Jamie B Smith; Mark S Kaiser; Michael L LeFevre
Journal:  Ann Fam Med       Date:  2020-01       Impact factor: 5.166

3.  Hypertension.

Authors:  James Brian Byrd; Robert D Brook
Journal:  Ann Intern Med       Date:  2019-05-07       Impact factor: 25.391

4.  Improvement of intestinal flora: accompany with the antihypertensive effect of electroacupuncture on stage 1 hypertension.

Authors:  Jun-Meng Wang; Ming-Xiao Yang; Qiao-Feng Wu; Ji Chen; Shu-Fang Deng; Lin Chen; Da-Neng Wei; Fan-Rong Liang
Journal:  Chin Med       Date:  2021-01-07       Impact factor: 5.455

5.  Effectiveness and Efficiency of Non-drug Therapy Among Community-Dwelling Adults With Hypertension in China: A Protocol for Network Meta-Analysis and Cost-Effectiveness Analysis.

Authors:  Taihang Shao; Xia Li; Chengchao Zhou; Xiao Zang; Daniel C Malone; Liang Zhang; Jifang Zhou; Wenxi Tang
Journal:  Front Med (Lausanne)       Date:  2021-02-25

6.  Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension.

Authors:  James P Sheppard; Sarah Stevens; Richard Stevens; Una Martin; Jonathan Mant; F D Richard Hobbs; Richard J McManus
Journal:  JAMA Intern Med       Date:  2018-12-01       Impact factor: 21.873

7.  Written Examinations in Swedish Medical Schools: Minds Molded to Medicate?

Authors:  Benno Krachler; Lars Jerdén; Christina Lindén
Journal:  Am J Lifestyle Med       Date:  2017-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.